A5067567761- Hepatitis C virus research
- Hepatitis B Virus Studies
- Liver Disease Diagnosis and Treatment
- Hepatitis Viruses Studies and Epidemiology
- HIV, Drug Use, Sexual Risk
- HIV/AIDS Research and Interventions
- Pharmaceutical Economics and Policy
- Health Systems, Economic Evaluations, Quality of Life
- HIV Research and Treatment
- Opioid Use Disorder Treatment
- Liver Disease and Transplantation
- Liver Diseases and Immunity
- Schizophrenia research and treatment
- Systemic Lupus Erythematosus Research
- Electroconvulsive Therapy Studies
- Healthcare Systems and Reforms
- Substance Abuse Treatment and Outcomes
- Artificial Intelligence in Healthcare
- Biotechnology and Related Fields
- Pneumonia and Respiratory Infections
- Medication Adherence and Compliance
- Machine Learning in Healthcare
- Intellectual Property and Patents
- Cytomegalovirus and herpesvirus research
- Drug-Induced Hepatotoxicity and Protection
Pharmacoeconomics and Health Outcomes Research Iberia (Spain)
2016-2025
Gobierno de La Rioja
2020
Abstract According to WHO goals, the elimination of Hepatitis C Virus (HCV) by 2030 requires enhancing and simplifying HCV testing. Our aim was create a model assess compare different strategies for testing, linkage care treatment among people who access harm reduction centres (HRC) Addiction Centres in Catalonia. A decision tree designed evaluate two strategies: Point‐of‐care (POC) “test treat”, at community versus standard‐of‐care (SOC), which testing performed therapy hospital. Both were...
Elimination of hepatitis C virus (HCV) infection requires high diagnostic rates and universal access to treatment. Around 40% infected individuals are unaware their infection, which indicates that effective screening strategies needed. We analyzed the efficiency (incremental cost-utility ratio, ICUR) 3 HCV strategies: a) general population adults, b) high-risk groups, c) with highest anti-HCV prevalence plus groups.An analytical decision model, projecting progression disease over a lifetime,...
To assess the long-term healthcare costs and health outcomes in association with access to new direct-acting antivirals (DAAs), during first year of National Strategic Plan for Chronic Hepatitis C (SPCHC) patients chronic hepatitis (CHC) Spain.A decision tree a lifetime Markov model were developed simulate natural history, morbidity, mortality cohort 51,900 CHC before (pre-DAA strategy) after (post-DAA DAAs, following SPCHC approval. The percentage treated, transition probabilities, disease...
Hepatitis C virus (HCV) infection affects 71 million people worldwide. The World Health Organization (WHO) has set a goal of HCV elimination by 2030, and this implies that 90% cases must be diagnosed 80% treated.1 To improve the diagnosis HCV, one-step approach (HCV-RNA reflex testing) was introduced in Spanish National System 2018. A high proportion patients with (mainly psychiatric or dependency individuals) are lost to follow-up (LTFU), likely because asymptomatic silent progression...
Abstract Background Patient access to orphan medicinal products (OMPs) is limited and varies between countries, reimbursement decisions on OMPs are complex, there a need for more transparent processes know which criteria should be considered inform these decisions. This study aimed determine the most relevant of in Spain, from multi-stakeholder perspective, using multicriteria decision analysis (MCDA). Methods An MCDA was developed 3 phases included 28 stakeholders closely related field rare...
•HCV/HBV prevalence at ED is threefold higher than that in the general population.•Forty percent of people living with HCV or HBV were unaware infection.•Risk factors for viral hepatitis not identified 60% those and 92% HBV.•Screening cost-effective. Background & AimsMany infection are their condition, particularly at-risk vulnerable populations who face barriers screening linkage to care. Emergency departments often only point contact health system.MethodsThis a prospective study...
Abstract Chronic hepatitis D (CHD) is a severe form of viral that leads to liver cirrhosis and hepatocellular carcinoma. CHD underdiagnosed, this study aimed assess the impact reflex testing in HBsAg‐positive individuals Spain over next 8 years. Two scenarios were compared: current situation (7.6% patients tested for anti‐HDV) all positive samples. A decision tree model was designed simulate care cascade. Implementing would increase anti‐HDV detection 5498 cases HDV‐RNA 3225 cases....
The prevalence of active hepatitis C virus (HCV) infection is higher in hospital emergency departments (EDs) than the general population. Numerous patients who seek care are unaware that they have detectable viremia, yet fall outside established ED protocols for HCV screening. Often belong to groups with difficult access health use as their point entry system. aim this consensus paper was develop an approach guide detection all Spanish hospitals. Experts from Society Emergency Medicine...
To evaluate the cost-effectiveness of ledipasvir/sofosbuvir (LDV/SOF) in treatment-naïve patients with chronic hepatitis C (CHC) genotype 1 (GT1) absence or mild fibrosis (F0-F1) versus advanced (F2-F4), from perspective Spanish Health System. A Markov model was developed to simulate disease progression, estimating costs and outcomes [life years gained (LYG) quality-adjusted life (QALY)] derived starting LDV/SOF F0-F1 compared F2-F4. Therapy duration 8 weeks noncirrhotic viral load <6...
We simulated the impact of implementing different health interventions to improve HIV continuum care for people diagnosed, on treatment, and virologically suppressed in Spain 2020–2030 period. The model was carried out four phases involving a multidisciplinary expert panel: (1) literature review; (2) selection/definition their effectiveness; (3) consensus meeting; (4) development an analytical decision project implementing/strengthening these care, corresponding 2017–2019 (87% 97% 90% with...
To evaluate the cost-effectiveness of direct-acting antiviral (DAAs) treatment versus non-treatment in prisoners awaiting for chronic hepatitis C (CHC) and to analyse clinical economic impact on liver complications mortality.A lifetime Markov model was developed simulate disease progression from an estimated cohort 4,408 CHC treated with DAAs over 2 years (50% patient each year) no treatment. In cohort, a sustained viral response 95% associated. Patient characteristics, transition...
Introduction Prevalence of chronic hepatitis C (CHC) is higher in patients born between 1955–1975. The aim was to perform an economic evaluation age-based electronic health record (EHR) alert primary care detect with undiagnosed CHC and its treatment comparison non-use the system, Valencian Community, Spain. Materials methods Decision trees Markov model were used evaluate diagnosis progression disease, respectively. diagnosed by serology viral load seropositive subjects. Epidemiological data...
The objective was to estimate the annual interaction management cost of agonist opioid treatment (AOT) for opioid-dependent (OD) patients with buprenorphine-naloxone (Suboxone®) (B/N) or methadone associated concomitant treatments infectious (HIV) psychiatric comorbidities. A costs analysis model developed calculate AOT and management. included pharmaceutical costs, drug preparation, distribution dispensing, based on intake regimen (healthcare center take-home) type frequency dispensing...